Magers & Quinn Booksellers

Cancel

Filters

Selected

Chang, Sand C., PhD

Condition

New

Used

Collectible

Availability

On Our Shelves

Ships from Warehouse

Format

Hardcover

Paperback

Audio Book

Other

Languages

English

Spanish

Italian

French

German

Portuguese

Chinese

Polish

Dutch

Latin

Price

Back

Chang, Sand C., PhD

Filters

Sort by

A Clinician's Guide to Gender-Affirming Care, Second Edition: Working with Trans and Nonbinary Clients

Chang, Sand C., PhD

Lpc

Audio Book

$55.99

A Clinician's Guide to Gender-Affirming Care, Second Edition: Working with Trans and Nonbinary Clients

Chang, Sand C., PhD

Lpc

Audio Book

$45.95

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

Chang, Sand C.

Paperback

$23.70

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

Chang, Sand C.

Audio Book

$39.99

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

Chang, Sand C.

Audio Book

$45.95

Fly, Wild Swans: My Mother, Myself and China

Chang, Jung, PhD

Audio Book

$49.99

A Clinician's Guide to Gender-Affirming Care: Working with Trans and Nonbinary Clients

Singh, Anneliese A.

Chang, Sand C.

Paperback

$56.95

Violations Of 21 CFR Part 58 - Good Laboratory Practice for Nonclinical Laboratory: Warning Letters Issued by U.S. Food and Drug Administration

Chang, C.

Paperback

$118.80

Violations Of 21 CFR Part 812 - Investigational Device Exemptions: Warning Letters Issued by U.S. Food and Drug Administration

Chang, C.

Paperback

$192.00

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts A-B: General Provisions and Quality System Requirements: Warning Letters Issued by U

Chang, C.

Paperback

$154.80

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart C Design Controls: Warning Letters Issued by U.S. Food and Drug Administration

Chang, C.

Paperback

$178.80

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts D-F: Document Controls, Purchasing Controls, Identification and Traceability: Warnin

Chang, C.

Paperback

$142.80

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart G Production and Process Controls: Warning Letters Issued by U.S. Food and Drug Adm

Chang, C.

Paperback

$168.00

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts H-I: Acceptance Activities and Nonconforming Product: Warning Letters Issued by U.S.

Chang, C.

Paperback

$178.80

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart J Corrective and Preventive Action: Warning Letters Issued by U.S. Food and Drug Ad

Chang, C.

Paperback

$192.00

Violations Of 21 CFR Part 820 Quality System Regulation: Subpart K- Labeling and Packaging Control, Subpart L- Handling, Storage, Distribution, and In

Chang, C.

Paperback

$118.80

Violations Of 21 CFR Part 56 - Institutional Review Boards: Warning Letters Issued by U.S. Food and Drug Administration

Chang, C.

Paperback

$118.80

Violations Of 21 CFR Part 312 - Investigational New Drug Application: Warning Letters Issued by U.S. Food and Drug Administration

Chang, C.

Paperback

$154.80

Violations Of 21 CFR Part 803 - Medical Device Reporting: Warning Letters Issued by U.S. Food and Drug Administration

Chang, C.

Paperback

$192.00

Violations Of 21 CFR Part 806 - Medical Devices; Reports Of Corrections And Removals: Warning Letters Issued by U.S. Food and Drug Administration

Chang, C.

Paperback

$118.80

Filters

Selected

Category

Condition

Availability

Format

Languages

Price

Chang, Sand C., PhD

A Clinician's Guide to Gender-Affirming Care, Second Edition: Working with Trans and Nonbinary Clients

A Clinician's Guide to Gender-Affirming Care, Second Edition: Working with Trans and Nonbinary Clients

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

Fly, Wild Swans: My Mother, Myself and China

A Clinician's Guide to Gender-Affirming Care: Working with Trans and Nonbinary Clients

Violations Of 21 CFR Part 58 - Good Laboratory Practice for Nonclinical Laboratory: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 812 - Investigational Device Exemptions: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts A-B: General Provisions and Quality System Requirements: Warning Letters Issued by U

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart C Design Controls: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts D-F: Document Controls, Purchasing Controls, Identification and Traceability: Warnin

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart G Production and Process Controls: Warning Letters Issued by U.S. Food and Drug Adm

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts H-I: Acceptance Activities and Nonconforming Product: Warning Letters Issued by U.S.

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart J Corrective and Preventive Action: Warning Letters Issued by U.S. Food and Drug Ad

Violations Of 21 CFR Part 820 Quality System Regulation: Subpart K- Labeling and Packaging Control, Subpart L- Handling, Storage, Distribution, and In

Violations Of 21 CFR Part 56 - Institutional Review Boards: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 312 - Investigational New Drug Application: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 803 - Medical Device Reporting: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 806 - Medical Devices; Reports Of Corrections And Removals: Warning Letters Issued by U.S. Food and Drug Administration

Loading

You have reached the end of the list.
Return to the top.

Filters

Selected

Category

Condition

Availability

Format

Languages

Price

Chang, Sand C., PhD

A Clinician's Guide to Gender-Affirming Care, Second Edition: Working with Trans and Nonbinary Clients

A Clinician's Guide to Gender-Affirming Care, Second Edition: Working with Trans and Nonbinary Clients

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

All Parts Welcome: The Queer and Trans Internal Family Systems Workbook

Fly, Wild Swans: My Mother, Myself and China

A Clinician's Guide to Gender-Affirming Care: Working with Trans and Nonbinary Clients

Violations Of 21 CFR Part 58 - Good Laboratory Practice for Nonclinical Laboratory: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 812 - Investigational Device Exemptions: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts A-B: General Provisions and Quality System Requirements: Warning Letters Issued by U

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart C Design Controls: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts D-F: Document Controls, Purchasing Controls, Identification and Traceability: Warnin

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart G Production and Process Controls: Warning Letters Issued by U.S. Food and Drug Adm

Violations Of 21 CFR Part 820 Quality System Regulation, Subparts H-I: Acceptance Activities and Nonconforming Product: Warning Letters Issued by U.S.

Violations Of 21 CFR Part 820 - Quality System Regulation, Subpart J Corrective and Preventive Action: Warning Letters Issued by U.S. Food and Drug Ad

Violations Of 21 CFR Part 820 Quality System Regulation: Subpart K- Labeling and Packaging Control, Subpart L- Handling, Storage, Distribution, and In

Violations Of 21 CFR Part 56 - Institutional Review Boards: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 312 - Investigational New Drug Application: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 803 - Medical Device Reporting: Warning Letters Issued by U.S. Food and Drug Administration

Violations Of 21 CFR Part 806 - Medical Devices; Reports Of Corrections And Removals: Warning Letters Issued by U.S. Food and Drug Administration

Loading

You have reached the end of the list. Return to the top.

You have reached the end of the list.
Return to the top.